Clinical findings indicate that hyperglycemia is critical in counterbalancing the therapeutic benefits and increasing the adverse complications of tPA through an action mode related to inflammation exacerbation [2,3,4,5]. The gene discussed is PLAT; the disease is Hyperglycemia.